Core Points - Cytokinetics has announced the eighth annual Communications Grant Program aimed at supporting patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure [2][3] - The program will award five grants to enhance communications, awareness, and community engagement within these patient communities [2][3] - The deadline for applications is November 3, 2025, with grant recipients to be announced in January 2026 [4] Group 1: Grant Program Details - The Communications Grant Program addresses a persistent funding gap in communications for patient advocacy organizations, which can hinder patient access to vital resources [3] - Grants may support programming or personnel, depending on the specific needs of the organizations [3] - Eligible organizations must be nonprofit or registered charities in the U.S., Canada, Europe, or the U.K., and serve HCM or heart failure patient communities [4] Group 2: Impact and Evaluation - Applications will be evaluated based on alignment with selection criteria, and recipients must provide an outcomes report to measure the impact of the funding [4] - The 2025 grant recipients include AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, Hypertrophic Cardiomyopathy Association, and Stichting Cardiomyopathie Onderzoek Nederland [3] Group 3: Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology and is advancing a pipeline of potential new medicines for cardiac muscle dysfunction [5] - The company is preparing for potential regulatory approvals for aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [5] - Other investigational medicines in development include omecamtiv mecarbil, ulacamten, and CK-089, targeting various heart failure and muscular dystrophy conditions [5]
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program